Extending Age Ranges in Breast Cancer Screening in Four European Countries: Model Estimations of Harm-to-Benefit Ratios.

Zielonke, Nadine; Geuzinge, Amarens; Heijnsdijk, Eveline A M; Heinävaara, Sirpa; Senore, Carlo; Jarm, Katja; de Koning, Harry J; van Ravesteyn, Nicolien T

Zielonke, Nadine; Geuzinge, Amarens; Heijnsdijk, Eveline A M; Heinävaara, Sirpa; Senore, Carlo; Jarm, Katja; de Koning, Harry J; van Ravesteyn, Nicolien T.

Afiliación

Zielonke N; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Geuzinge A; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Heijnsdijk EAM; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Heinävaara S; Finnish Cancer Registry, Mass Screening Registry, 00130 Helsinki, Finland.
Senore C; Epidemiology and screening Unit-CPO, University Hospital Città della Salute e della Scienza, 10126 Turin, Italy.
Jarm K; Epidemiology and Cancer Registry, Institute of Oncology, 1000 Ljubljana, Slovenia.
de Koning HJ; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
van Ravesteyn NT; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.

Cancers (Basel) ; 13(13)2021 Jul 04.

Article en En | MEDLINE | ID: mdl-34283068

Palabras clave

breast cancer deaths averted; breast cancer screening; false-positive results; harm-to-benefit ratios; microsimulation; overdiagnosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google